An Introduction to Prostate Cancer
The management of prostate cancer has evolved rapidly over the last decade. There are now several approved treatments in the castration-resistant treatment setting, delivering significant benefits like overall survival rate. The androgen receptor-targeting agents are also now proving effective in the hormone-sensitive setting.
Browse the content below where leading experts, discuss the latest data in video interviews and short articles from our conference hub and browse the selection of peer-reviewed articles from our journal portfolio. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Prostate Cancer Content
PSMA-targeted radiopharmaceuticals: An evolving approach to prostate cancer management
Three experts discuss data presented at ESMO 2023 on PSMA-targeted radiopharmaceuticals in prostate cancer.
- Describe potential strategies to refine selection of patients with advanced prostate cancer for treatment with PSMA-targeting radiopharmaceuticals
- Outline how the latest data for PSMA-targeting radiopharmaceuticals may impact the timing of their use in patients with advanced prostate cancer
- Analyse the latest data on radiopharmaceuticals in advanced prostate cancer, including combination strategies and novel agents in clinical development
ARPi vs. SOC and taxanes in mCRPC – ProBio study: Henrik Grönberg, EMSO 2023
The uniquely designed Prostate Biomarker (ProBio) study (NCT03903835) used outcome-adaptive randomization to compare biomarker-driven treatment selection against physician’s choice, and to compare androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC). To learn more about the trials unique design, the details surrounding the biomarker signatures investigated and the treatments compared, […]
Optimizing androgen deprivation therapy (ADT) in advanced prostate cancer
Watch three experts discuss the risks and benefits of ADT, the barriers to equitable care and how to improve treatment adherence in prostate cancer.
- Review the risks and benefits of gonadotropin-releasing hormone agonists and antagonists in the treatment of advanced prostate cancer
- Discuss strategies to promote equitable care and address disparities in prostate cancer treatment outcomes
- Evaluate ways to incorporate patient preferences and improve adherence to ADT in clinical practice
Arnulf Stenzl: Highlights from EAU23!
touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors. Topics […]
Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years
Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses the most important recent advances in the treatment landscape for prostate cancer, including screening using MRI and PSMA PET-CT scans, and triplet therapies using hormone therapy and PARP inhibitors. He also takes a look to the future, discussing developments he hopes to see in early detection, […]
Axel Merseburger: Highlights of EAU23
Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses key data from this year’s European Association of Urology annual meeting (EAU23) in the field of prostate cancer. He discusses results from the LuTectomy trial, the 15-year update of the ProtecT trial and the PROBASE trial. Question: Please summarize the most important presentations and data from […]
Fred Saad, ESMO 2022: Highlights in prostate cancer – Phase 3 trials in the STAMPEDE platform protocol
Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss clinical trial highlights in prostate cancer presented at EMSO 2022. He highlights the results from one of the phase 3 STAMPEDE trials, investigating combination abiraterone and enzalutamide or abiraterone and prednisolone, for metastatic hormone sensitive prostate cancer (mHSPC), […]
Fred Saad, ESMO 2022: Phase 3 PROpel trial of abiraterone and olaparib for patients with prostate cancer – Biomarker analysis and updated results
In the PROpel trial, abiraterone and olaparib significantly prolonged radiographic progression free survival in patients with metastatic castration-resistant prostate cancer. Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss the biomarker analysis from the primary analysis, and updated overall survival and safety data. The abstract entitled ‘Biomarker […]
Is Triple Therapy the New Standard for Metastatic Hormone-sensitive Prostate Cancer?
touchREVIEWS in Oncology & Haematology 2022;18(2):120-4 DOI: https://doi.org/10.17925/OHR.2022.18.2.120
Androgen deprivation therapy (ADT) has been the cornerstone of the treatment of metastatic prostate carcinoma for over 70 years, ever since Huggins and Hodges first treated men with prostate carcinoma with orchidectomy or oestrogen injection in 1941.1 However, the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has changed rapidly over the past decade, with level […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!